← Oncology Approval Tracker

FDA DECISION ·

Ayvakit

avapritinib · Blueprint Medicines

FDA approvalNew therapyGastrointestinal stromal tumor
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with unresectable or metastatic gastrointestinal stromal tumor with a PDGFRA exon 18 mutation, including D842V.

LAMPGEN ANALYSIS

Why it matters

Opened an approved targeted option for a mutation associated with resistance to earlier kinase inhibitors.

What research teams should watch

Build in exon-level genomic reporting and monitor for cognitive adverse effects.

PRIMARY RECORDS

Sources